The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.
Philip Morris International PM
Outside both standards
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Philip Morris International Inc.
read at $193.00
Philip Morris International holds its Markup at $193.00.
- PHPhase · the trend structure carries the Markup label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · does not pass the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 10 days |
| Price | $193.00 |
| Valuation | 26.51 trailing · 21.12 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 0.41 |
The opportunity · what the numbers say it is worth
Our framework reads AVOID — it trades at roughly a 2% discount to our $195.90 fair value, 10.40% revenue growth.
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
| Revenue growth | 10.40% |
| Profit margin | 25.56% |
| Analyst consensus | Buy · 15 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company is excluded by both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. It fails on both:
Used by most halal investing apps ✗ DOES NOT PASS
The one Titan applies ✗ DOES NOT PASS
Why it fails. The problem is its business activity screen. Because both standards agree on this, it is a clear exclusion, not a borderline case.
What these two standards are, and how they differ →
- Business activity Business activity: Tobacco Fail
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Tobacco profits still fail the ethics test
Walk into any corner shop from Manila to Moscow and the familiar packs sit right by the till. Philip Morris keeps selling them, along with newer heated and nicotine products, at a 27 percent profit margin and 9 percent revenue growth. The shares trade at 21 times forward earnings, almost exactly at our fair value.
We pass for one clear reason. The business activity screen rules out tobacco outright, regardless of how defensive the cash flows look or how many analysts still rate the stock a buy with a 200 dollar median target. Numbers alone do not override that filter.
Margins this high reflect an industry built on addiction, not innovation, and the ethical line exists to keep that reality front of mind. Analysis, not advice.
| Forward P/E | 21.1x expensive even after accounting for its growth |
| Trailing P/E | 26.5x a premium valuation |
| Revenue growth | 10.4% steady growth |
| Profit margin | 25.6% healthy profit margins |
| Current ratio | 0.98 below 1 — short-term bills exceed liquid assets |
| Beta | 0.41 barely tracks the market's swings |
| Market cap | $300.8B |
| Employees | 84,900 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Latest news · what the market is reading on PM
- › Altria Stock Trades Below The Market On Earnings And Above It On Sales Trefis · 17h ago
- › 5 High-Yielding Dividend Stocks for Retirees to Buy and Hold Forever 24/7 Wall St. · 3d ago
- › Why Did AAPL, KO, PM Stocks Jump To 52-Week Highs Today? Stocktwits · 3d ago
- › Altria Group (MO): A Winner in President Trump’s Stock Portfolio? Insider Monkey · 4d ago
- › Should You Buy Altria for Its 5.8% Dividend Yield Ahead of July 30 Earnings? 24/7 Wall St. · 4d ago
Headlines from third-party outlets, linked for reference — not our reporting, not advice.
Related securities · others in PM's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
PM trades on a US exchange. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
The insider ledger · Form 4 filings, as filed
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-06 | CALANTZOPOULOS ANDRE | Chairman of the Board | 1,119 | $190,152 | |
| 2026-05-06 | HARKER VICTORIA D | Director | 1,119 | $190,152 | |
| 2026-05-06 | GEISSLER WERNER | Director | 1,119 | $190,152 | |
| 2026-05-06 | HOOK LISA A. | Director | 1,119 | $190,152 | |
| 2026-05-06 | BOUGH BONIN | Director | 1,119 | $190,152 | |
| 2026-05-06 | COMBES MICHEL | Director | 1,119 | $190,152 | |
| 2026-05-06 | POLET ROBERT | Director | 1,119 | $190,152 | |
| 2026-05-06 | YANAI SHLOMO | Director | 1,119 | $190,152 | |
| 2026-05-06 | MORPARIA KALPANA | Director | 1,119 | $190,152 | |
| 2026-02-20 | DOBROWOLSKI REGINALDO | Officer | 6,000 | $1,100,880 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
The political ledger · congressional disclosures
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 7 May2026 | Ro Khanna | Democrat | sell | 1K–15K |
| 26 May2026 | Dave McCormick | Republican | sell | 100K–250K |
| 26 May2026 | Dave McCormick | Republican | sell | 100K–250K |
| 2026-05-08 | Bill Keating | Democrat | Purchase | 1K–15K |
| 2026-04-24 | Ro Khanna | Democrat | Purchase | 1K–15K |
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $182.11 | +0.3% | · | $1,003 | +0.3% |
| 2 months | $160.45 | +13.9% | · | $1,139 | +13.9% |
| 3 months | $170.48 | +7.2% | $1.47 | $1,080 | +8.0% |
| 6 months | $148.26 | +23.2% | $2.94 | $1,252 | +25.2% |
| 1 year | $172.90 | +5.7% | $5.76 | $1,090 | +9.0% |
| 2 years | $95.83 | +90.7% | $11.11 | $2,023 | +102.3% |
| 3 years | $81.02 | +125.5% | $16.28 | $2,456 | +145.6% |
| 5 years | $77.95 | +134.4% | $26.29 | $2,681 | +168.1% |
Historical returns from market close data. Past performance does not guarantee future results.